Navigation Links
Royalty Rates Take Center Stage in Biopharma Dealmaking
Date:11/14/2012

ATLANTA, Nov. 14, 2012 /PRNewswire-USNewswire/ -- One-by-one, big pharmaceutical firms are plunging off patent cliffs. They're scrambling to fill pipelines and reinforce bottom lines. The door is open wider than ever for biotechnology companies and their coffers of innovative therapeutic candidates to negotiate lucrative licensing deals with a focus on royalty rates. New data from BioWorld reveal that biotechs can garner higher rates from a pharma partner than any other licensee.

(Logo:  http://photos.prnewswire.com/prnh/20120628/DC32901LOGO)

The average royalty rate for deals with a pharma licensee is 14.9% at the high end and 11.74% at the low end, while other deals (ex: other biotechs) command average royalty rates between 9.88% and 6.39%, according to Biopharmaceutical Royalty Rates Analysis: Essential Benchmarks for Dealmaking, a new BioWorld Data tool that analyzes hundreds of licensing deals to provide a tangible starting point for deal negotiations.

Drugs to treat pain are garnering the highest average royalty rate of 14.7% at the high end and 8.5% at the low end.

"Just last month, on the eve of reporting 3Q earnings, Eli Lilly and Co.'s Fitch Rating was lowered from stable to negative due to Lilly's looming patent cliff, called the steepest in the industry by Fitch, due to anticipated losses of antidepressant Cymbalta and Type I diabetes drug Humalog next year," said Lynn Yoffee, BioWorld's executive editor. "Partnering and dealmaking are a matter of survival. The extra tough economy has forced drug developers to sharpen their dealmaking skills. To help drugmakers at the negotiating table, we've analyzed >300 licensing deals to provide an array of average and median royalty rates and up-front licensing fees to help these negotiators with details that can be used as benchmarks and comparators."

The report includes a variety of analyses, including a deeper dive into certain hot disease areas such as Alzheimer's and hepatitis. Backing up the analyses are profiles of more than 320 deals including all deal terms and key background information on the drug or drug technology in focus.

For access to BioWorld's Biopharmaceutical Royalty Rates Analysis: Essential Benchmarks for Dealmaking visit www.bioworld.com/royaltyrates or call 800-888-3912.

BioWorld Today, and its analytical companion, BioWorld Insight, are the biopharmaceutical industry's most respected news sources and have been for more than two decades. All of that information is now leveraged in BioWorld Data, business intelligence for biopharmaceutical executives.

CONTACT: Lynn Yoffee, Executive Editor, +1-404-262-5408


'/>"/>
SOURCE BioWorld
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. STAAR Surgical Celebrates Over 300,000 Successful Visian® ICL Implants at ASCRS Congress
2. Henry Schein Celebrates Earth Day
3. OncoSec ElectroChemotherapy Demonstrates Potential as Alternative to Surgery for Treating Head and Neck Cancer
4. Shire Delivers Strong First Quarter Performance and Reiterates its Expectation of Good Full Year Earnings Growth
5. New Data to be Presented at the Annual American Thoracic Society International Conference Demonstrates Depth of Boehringer Ingelheim Respiratory Research Pipeline
6. Former NxStage Patient Nikolas Gieske Celebrates Kidney Transplant
7. AXIOS™ Stent and Delivery System Study Demonstrates Successful Treatment of Pancreatic Pseudocysts and Acute Cholecystitis
8. Inovio Pharmaceuticals Universal Avian Flu Vaccine Generates Protective Antibody Responses Against Six H5N1 Viruses in Phase I Trial
9. Liberty Dialysis Celebrates Milestone 1,000th Patient in Peritoneal Dialysis Program
10. Ceregene Parkinsons Disease Study Demonstrates Long-term Neurturin Expression and Enhanced Dopamine Activity 4 Years Following Delivery of CERE-120 (AAV2-neurturin)
11. BIOCRATES Life Sciences to Launch Waters Xevo® TQ MS Editions for Two of its Well-established Research Kit Products, AbsoluteIDQ® p180 and p150
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/23/2017)... , Jan. 23, 2017 The Pharmacy ... the implementation of the planned 2020 accredited education ... PTCB originally announced in 2013 that the requirement ... a road map of program changes designed to ... in the pharmacy. "We have ...
(Date:1/23/2017)... 2017  Therabron Therapeutics, Inc., a clinical-stage biotechnology ... respiratory care, today announced that the European Medicines ... granted Orphan Drug Designation for Therabron,s CG367 program, ... (BOS).  "We are pleased to have ... treat patients diagnosed with BOS following lung transplantation. ...
(Date:1/23/2017)... -- Research and Markets has announced the addition of ... report to their offering. ... The interventional radiology products market is expected to reach ... at a CAGR of 4.8%. This market is segmented based on ... the growth of this market are rising incidence of chronic diseases, ...
Breaking Medicine Technology:
(Date:1/24/2017)... ... 2017 , ... A yellow fever outbreak in Brazil has infected over 100 ... primarily spread through contact with infected mosquitos. The outbreak has sparked increased concern about ... , According to multiple health organizations, the best way to prevent yellow fever is ...
(Date:1/24/2017)... ... January 24, 2017 , ... “Choosing Wisdom-Solomon’s Proverbs ... friendship, marriage, leadership, gossip, prostitution, adultery, anger, and common sense. , “Choosing ... Coats and Dr. David Coats. In September of 1983, they flew to Haiti ...
(Date:1/24/2017)... ... January 24, 2017 , ... “Mysteries Revealed On Speaking In Tongues”: ... phenomenon is available to all Christians. “Mysteries Revealed On Speaking In Tongues” is the ... Creation,” a Christian-based talk show located in Michigan. , “We need to partner ...
(Date:1/24/2017)... ... January 24, 2017 , ... Attention women who want ... suggests that autologous fat grafting—taking one’s own fat and putting it in other ... , Cosmetic Surgeon and Medical Director of MilfordMD Cosmetic Dermatology Surgery & ...
(Date:1/24/2017)... IL (PRWEB) , ... January 23, 2017 , ... ... is partnering with Plug and Play, the world’s largest start-up platform headquartered in ... companies a year. , OSF Ventures recently signed a three-year agreement to ...
Breaking Medicine News(10 mins):